Chandan Healthcare Proposes ₹50 Crore Shift Toward Diagnostic Expansion

Board recommended reallocating Rs 50 Cr of unutilised warrant proceeds from acquisitions to new diagnostic laboratories and comprehensive centres; proposed Sanjay Srivastava as independent director. The reallocation supports Chandan's diagnostics-focused expansion strategy and shifts capital toward building its own network rather than acquiring existing units. Shareholder special-resolution approval is required on 30 September 2026; warrant issue price, conversion terms and exercise period remain unchanged, with execution timelines not disclosed.